At the time of writing, Silence Therapeutics Plc ADR [SLN] stock is trading at $5.66, up 5.40%. An important factor to consider is whether the stock is rising or falling in short-term value. The SLN shares have gain 8.02% over the last week, with a monthly amount glided 14.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Silence Therapeutics Plc ADR [NASDAQ: SLN] stock has seen the most recent analyst activity on February 11, 2025, when Goldman initiated its Sell rating and assigned the stock a price target of $6. Previously, BMO Capital Markets reaffirmed its Outperform rating on December 02, 2024. On September 03, 2024, Jefferies initiated with a Buy rating and assigned a price target of $40 on the stock. BMO Capital Markets started tracking the stock assigning a Outperform rating and suggested a price target of $67 on January 31, 2024.
For the past year, the stock price of Silence Therapeutics Plc ADR fluctuated between $1.97 and $22.47. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Silence Therapeutics Plc ADR [NASDAQ: SLN] shares were valued at $5.66 at the most recent close of the market. An investor can expect a potential return of 907.07% based on the average SLN price forecast.
Analyzing the SLN fundamentals
According to Silence Therapeutics Plc ADR [NASDAQ:SLN], the company’s sales were 20.57M for trailing twelve months, which represents an -94.53% plunge. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -2.76%, Pretax Profit Margin comes in at -2.0%, and Net Profit Margin reading is -2.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.87 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.31 points at the first support level, and at 4.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.93, and for the 2nd resistance point, it is at 6.20.
Ratios To Look Out For
It is important to note that Silence Therapeutics Plc ADR [NASDAQ:SLN] has a current ratio of 8.81. On the other hand, the Quick Ratio is 8.81, and the Cash Ratio is -3.37. Considering the valuation of this stock, the price to sales ratio is 13.00, the price to book ratio is 2.37.
